A hedge fund insider-trading case has ensnared a former Food and Drug Administration official, one of the first criminal actions focused on how Wall Street gathers information from Washington.
Federal prosecutors on June 15 unveiled charges against a current and a former portfolio manager of hedge- fund firm Visium Asset Management, accusing them of trading on confidential government information about generic-drug approvals.
